In this article, we take a look at two stocks which have been in news recently, AcelRx Pharmaceuticals (ACRX) & Nymox Pharmaceuticals (NYMX). Keep an eye out for both these active stocks which have been performing well on the wall street.
AcelRx Pharmaceuticals (ACRX) should win FDA approval for the Zalviso pain-killing device on July 27. The Zalviso phase III studies were all well designed and positive. The painkiller in Zalviso is a tiny sublingual (under the tongue) tab of sufentanil, which is already FDA approved for intravenous use. Regulators aren’t likely to be concerned about approving a new formulation of a proven drug. The biggest risk to approval is if FDA finds an unresolved problem with the Zalviso dispensing device or the software which runs it, but again, no issues appeared to crop up in the clinical trials.
Nymox Pharmaceuticals (NYMX) has a market cap of approximately $163 million and has had very good results to date on its NX-1207 drug for benign prostastic hyperplasia (BPH). The company just completed a phase III study of NX-1207 with no results released yet.
AcelRx Pharmaceuticals (ACRX) & Nymox Pharmaceuticals (NYMX)
Zalviso works like a high-tech Pez dispenser, except instead of a small brick of flavored sugar, the device doles out an even tinier, dissolvable sufentanil pill for patients in the hospital recuperating from surgery. AcelRx is developing Zalviso to replace the so-called “IV PCA” delivery of morphine for post-surgical hospital patients.
Nymox completed a small phase II study using this drug at a higher dose for low-grade prostate cancer with good results showing lower Gleason and PSA scores. An Italian pharmaceutical company, Recordati, bought European rights to NX-1207 and undoubtedly did extensive due diligence.
Biotech News Video
Watch this video for more “Biotech” news.
Biotech Financial News
Both the stocks AcelRx Pharmaceuticals (ACRX) & Nymox Pharmaceuticals (NYMX) would look to have a bullish run in the near future. They have both been around some very encouraging news. How the stocks respond to the change of guard remains to be seen.
Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.